Valence Discovery: transforming AI-enabled drug design : vim

Valence Discovery: transforming AI-enabled drug design


Darcy Jimenez
1 April 2021 (Last Updated March 31st, 2021 17:44)
The use of artificial intelligence to support drug discovery and design efforts is a rapidly expanding field, with new players looking to streamline AI’s role in drug discovery and translation. One such player is Montreal-headquartered Valence Discovery, which is looking to capture the clinical insights of ‘few-shot learning’.
Artificial intelligence has become an increasingly popular tool for drug companies discovering and designing new therapies. Credit: Shutterstock
Share Article
Artificial intelligence (AI) has become an increasingly popular tool for drug companies discovering and designing new therapies. According to analysis by Deloitte, the AI market in drug discovery is expected to grow from $159.8m in 2018 to $2.9bn by 2025.

Related Keywords

Canada , France , French , Canadian , Yoshua Bengio , Daniel Cohen , Deloitte , Institute For Research , Valence Discovery , Professor Yoshua Bengio , Repare Therapeutics , கனடா , பிரான்ஸ் , பிரஞ்சு , கனடியன் , டேனியல் கோஹன் , டெலோய்ட்டே , நிறுவனம் க்கு ஆராய்ச்சி , வேலன்ஸ் கண்டுபிடிப்பு , சரிசெய்ய சிகிச்சை ,

© 2025 Vimarsana